Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Living Cell TechnologiesBriacell TherapeuticsOvoca BioBiopharmxMedibio
Price Information
Current PriceA$0.01C$10.39GBX 12$0.51A$0.01
52 Week RangeN/AN/AN/AHoldN/A
Beat the Market™ Rank
Overall Score0.
Analysis Score0.
Community Score2.
Dividend Score0.
Ownership Score0.
Earnings & Valuation Score0.
Analyst Ratings
Consensus RecommendationN/AN/AN/AHoldN/A
Consensus Price TargetN/AN/AN/A$12.00N/A
% Upside from Price TargetN/AN/AN/A2,252.94% upsideN/A
Trade Information
Market Cap$7.43 millionC$6.49 million£9.79 million$75.12 million$6.97 million
Average VolumeN/A966N/A2,150,348N/A
Sales & Book Value
Annual Revenue$708,094.00N/AN/AN/A$1.47 million
Price / Sales10.49N/AN/AN/A4.73
CashflowA$0.01 per shareC$0.13 per shareN/AN/AA$0.00 per share
Price / Cash2.1779.92N/AN/A3.50
Book ValueA$0.01 per shareC($4.14) per shareGBX 25.70 per shareN/AA$0.01 per share
Price / Book1.86N/AN/AN/A0.54
Net IncomeN/AN/AN/AN/AN/A
EPSA$0.00C($10.14)GBX (2)N/AA($0.01)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E Ratio
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt-to-Equity Ratio6.99%48.40%4.80%N/A1.02%
Current Ratio9.82%0.08%28.57%N/A1.53%
Quick Ratio9.73%0.03%23.52%N/A1.49%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Shares Outstanding571.44 million722,00081.56 million18.28 million995.13 million
Next Earnings DateN/A6/25/2020 (Estimated)N/A6/9/2020 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.